Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Infographic: CAR-T Cells in Solid Versus Liquid Cancers

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

immune checkpoint blocker
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Catherine Offord | Jan 15, 2019
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
Fecal Transplant Heals Colitis Caused by Immunotherapy
Fecal Transplant Heals Colitis Caused by Immunotherapy
Anna Azvolinsky | Nov 12, 2018
A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.
Opinion: Learning from Immunotherapy’s Recent Failures
Opinion: Learning from Immunotherapy’s Recent Failures
Luis Felipe Campesato | Aug 1, 2018
The promise of immunotherapy is real. We now need to figure out how to maximize the number of patients the approach benefits.
Immunotherapy More Effective in Men: Study
Immunotherapy More Effective in Men: Study
Kerry Grens | May 18, 2018
Women with metastatic cancer who were treated with a checkpoint inhibitor had a smaller benefit than did men.
The Cancer Genes Needed for Immunotherapy Response
The Cancer Genes Needed for Immunotherapy Response
Anna Azvolinsky | Aug 7, 2017
Using a large CRISPR-based screen, researchers find possible genetic culprits for patients not having success with immune checkpoint inhibitors.  
Gene Mutations Foretell Immunotherapy Response
Gene Mutations Foretell Immunotherapy Response
Aggie Mika | Jun 12, 2017
A drug that blocks an immune checkpoint protein effectively treats tumors in patients with deficient DNA repair genes.